Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma

Acta Obstetricia et Gynecologica Scandinavica

Volumn 79, Issue 4, 2000, Pages 311-316

  Sakuragi, Noriaki ^a   Hareyama, Hitoshi ^a   Todo, Yukiharu ^a   Yamada, Hideto ^a   Yamamoto, Ritsu ^a   Fujino, Takafumi ^a   Sagawa, Tadashi ^a   Fujimoto, Seiichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Clear cell adenocarcinoma; Endometrial carcinoma; Lymph node metastasis; Serous adenocarcinoma; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; CLEAR CELL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SALPINGOOOPHORECTOMY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034016987     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2000.079004311.x     Document Type: Article

References (29)

1. Eifel PJ, Ross J, Hendrickson M, Cox RS, Kempson R, Martinez A. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 1983; 52: 1026-31.
2. Webb GA, Lagios MD. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol 1987; 156: 1486-91.
3. Wilson TO, Podratz KC, Gaffey TA, Malkasian GD, O'Brien PC, Naessens JM. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990; 162: 418-26.
4. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathologic study of 22 cases. Gynecol Oncol 1990; 39: 266-71.
5. Greven KM, Lanciano RM, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 1993; 71: 3697-702.
6. Lampe B, Kurzl R, Hantschmann P. Prognostic factors that predict pelvic lymph node metastasis from endometrial carcinoma. Cancer 1994; 74: 2502-8.
7. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54: 264-8.
8. Grice J, Ek M, Greer B, Koh W-J, Muntz HG et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998; 69: 69-73.
9. Clement PB, Scully RE. Endometrial hyperplasia and carcinoma. In: Clement PB, Young RH, eds. Tumors and tumorlike lesions of the uterine corpus and cervix. New York: Churchill Livingstone, 1993: 181-264.
10. FIGO (International Federation of Gynecology and Obstetrics), FIGO News, Corpus cancer staging. Int J Gynaecol Obstet 1989; 28: 189-93.
11. Kurman RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, Norris HJ, eds. Blaustein's pathology of the female genital tract. 3rd ed. New York: Springer, 1987: 338-72.
12. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981; 105: 615-18.
13. Hendrickson MR, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93-108.
14. Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol 1985; 4: 279-88.
15. Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol 1986; 67: 670-4.
16. Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol Oncol 1987; 27: 294-304.
17. Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol 1987; 69: 109-13.
18. Ramirez-Gonzalez CE, Adamsons K, Mangual-Vazquez TY, Wallach RC. Papillary adenocarcinoma in the endometrium. Obstet Gynecol 1987; 70: 212-15.
19. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. H. Papillary adenocarcinoma: a clinical pathological study, 46 cases. Am J Clin Pathol 1982; 77: 534-40.
20. Descamps P, Calais G, Moire C, Bertrand P, Castiel M, Le Floch O et al. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol 1997; 64: 54-8.
21. Malpica A, Tornos C, Burke TW, Silva EG. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995; 19: 769-74.
22. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61: 167-74.
23. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22: 1463-73.
24. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994; 74: 1778-83.
25. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29: 551-8.
26. Bancher-Todesca D, Neuteufel W, Williams KE, Prainsack D, Breitenecker G, Friedlander ML et al. Influence of post-operative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998; 71: 344-7.
27. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999; 74: 272-7.
28. Price FV, Amin RM, Sumkin J. Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma. Gynecol Oncol 1999; 73: 140-4.
29. Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 1999; 73: 461-3.